How effective is Lisocabtagene maraleucel (Beryanzi)?

Lisocabtagene maraleucel(Beryanzi) has achieved certain efficacy in clinical trials, especially showing potential positive effects in the treatment of patients with refractory or relapsed large Bcell lymphoma (DLBCL). Please note that this information is based on the results of early clinical trials and studies and therefore may change over time.

Based on some preliminary results from clinical trials, Lisocabtagene maraleucel’s efficacy in DLBCL patients includes:

1.Response rate:Lisocabtagene maraleucelhas been shown to have higher tumor response rates in DLBCL patients in some studies, even those who have previously received other treatments but whose disease has progressed may also benefit.

2.Sustained remission: Some DLBCL patients who receive Lisocabtagene maraleucel treatment can achieve sustained remission, that is, rapid tumor reduction and remaining in remission for subsequent months or years.

3.Individualization of treatment response:CAR-TCell therapies such asLisocabtagene maraleucel are highly individualized treatments, so the efficacy can vary depending on the patient's specific situation. Some patients may experience better results from treatment, while others may have less noticeable results.

Although preliminary results suggest that Lisocabtagene maraleucel has potential efficacy in some DLBCL patients, this treatment also comes with the risk of serious side effects, such as cytokine release syndrome (CRS) and neurological toxicity. Therefore, treatment selection and monitoring needs to be under the guidance of a medical professional and requires an in-depth discussion between doctor and patient to weigh potential benefits and risks. If you or someone you know is considering this treatment, it is recommended to consult a medical professional for the latest information and advice.